Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice

Katô, Hirofumi; Takayama-Ito, Mutsuyo; Iizuka-Shiota, Itoe; Fukushi, Shuetsu; Posadas-Herrera, Guillermo; Horiya, Madoka; Satoh, Masaaki; Yoshikawa, Tomoki; Yamada, Souichi; Harada, Shizuko; Fujii, H.; Shibamura, Miho; Morimoto, Kanehisa; Saijo, Masayuki; Lim, Chang‐Kweng

doi:10.1371/journal.pone.0223684

Cited by 18 publications

(16 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a live recombinant vesicular stomatitis virus (VSV) displaying the S protein of MERS-CoV instead of the G protein induced both humoral and cell-mediated immunities in vaccinated rhesus macaques after a single dose of immunization [ 137 ]. More recently, Kato et al developed a novel bivalent RVΔP-MERS/S1 vaccine against rabies virus (RV) and MERS-CoV using a replication-incompetent P-gene-deficient RV (RVΔP) [ 138 ]. Using a reverse genetics method, the recombinant RVΔP was used to express S1 fused to transmembrane and cytoplasmic domains together with 14 amino acids from the ectodomain of the RV-glycoprotein (RV-G).…”

Section: Control Approaches For Mers-covmentioning

confidence: 99%

See 1 more Smart Citation

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science

et al. 2020

View full text Add to dashboard Cite

Coronaviruses belong to a large family of viruses that can cause disease outbreaks ranging from the common cold to acute respiratory syndrome. Since 2003, three zoonotic members of this family evolved to cross species barriers infecting humans and resulting in relatively high case fatality rates (CFR). Compared to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV, CFR = 10%) and pandemic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, CFR = 6%), the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has scored the highest CFR (approximately 35%). In this review, we systematically summarize the current state of scientific knowledge about MERS-CoV, including virology and origin, epidemiology, zoonotic mode of transmission, and potential therapeutic or prophylactic intervention modalities.

show abstract

Section: Control Approaches For Mers-covmentioning

confidence: 99%

“…In RVΔP-MERS/S1- and RVΔP-vaccinated mice, there were no rabies-associated signs or symptoms. Serologically, RVΔP-MERS/S1 induced specific neutralizing antibodies against both MERS-CoV and RV following its intraperitoneal injection [ 138 ].…”

Section: Control Approaches For Mers-covmentioning

confidence: 99%

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science

et al. 2020

View full text Add to dashboard Cite

show abstract

“…No approved vaccines or specific treatments are yet available against SARS‐CoV, MERS‐CoV infection for potential therapy of humans. So many researchers are trying to develop a vaccine using a variety of platforms (Graham, Donaldson, & Baric, 2013; Kato et al., 2019; Schindewolf & Menachery, 2019). It may take months and years to develop particular vaccines for such a rapidly mutating SARS‐CoV‐2 as these studies are in progress and more laboratory and clinical trials still should be explored.…”

Section: Possible Vaccines For Covid‐19 Pneumoniamentioning

confidence: 99%

The recent challenges of highly contagious COVID‐19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy

Mohapatra¹,

et al. 2020

View full text Add to dashboard Cite

COVID‐19 is highly contagious pathogenic viral infection initiated from Wuhan seafood wholesale market of China on December 2019 and spread rapidly around the whole world due to onward transmission. This recent outbreak of novel coronavirus (CoV) was believed to be originated from bats and causing respiratory infections such as common cold, dry cough, fever, headache, dyspnea, pneumonia, and finally Severe Acute Respiratory Syndrome (SARS) in humans. For this widespread zoonotic virus, human‐to‐human transmission has resulted in nearly 83 lakh cases in 213 countries and territories with 4,50,686 deaths as on 19 June 2020. This review presents a report on the origin, transmission, symptoms, diagnosis, possible vaccines, animal models, and immunotherapy for this novel virus and will provide ample references for the researchers toward the ongoing development of therapeutic agents and vaccines and also preventing the spread of this disease.

show abstract

“…77 This vaccine is considered a promising bivalent vaccine candidate because it can safely and effectively induce mice to produce MERS-CoV-and RV-specific NAbs. 77 A recent study showed that the recombinant vaccine using RV as a virus vector and expressing the MERS-CoV S1 (spike) protein on the RV surface could elicit a very high antibody response, and compared to granular element method-particle vectored vaccines, the cellular immune level was significantly higher. 78 These findings provide a theoretical basis for the development of MERS-CoV vaccines.…”

Section: Recombinant Protein Subunit Vaccinesmentioning

confidence: 99%

Research progress and challenges to coronavirus vaccine development

Zhou

Xie³

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

Coronaviruses (CoVs) are nonsegmented, single-stranded, positive-sense RNA viruses highly pathogenic to humans. Some CoVs are known to cause respiratory and intestinal diseases, posing a threat to the global public health. Against this backdrop, it is of critical importance to develop safe and effective vaccines against these CoVs. This review discusses human vaccine candidates in any stage of development and explores the viral characteristics, molecular epidemiology, and immunology associated with CoV vaccine development. At present, there are many obstacles and challenges to vaccine research and development, including the lack of knowledge about virus transmission, pathogenesis, and immune response, absence of the most appropriate animal models. K E Y W O R D S animal model, coronavirus, receptor-binding domain, spike protein, vaccine 1 | INTRODUCTION Coronaviruses (CoVs) are a large family of viruses with some causing mild to moderate illnesses like the common cold and others bringing severe diseases such as Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). At the end of 2019, emerging infections caused by a novel CoV were reported in Wuhan, China. Most of the early reported cases came from the South China Seafood Wholesale Market in Wuhan, China, which is now closed and disinfected. The virus was identified as a new CoV and officially named by The International Committee on Taxonomy of Viruses as SARS-CoV-2 (previously provisionally named 2019 novel coronavirus or 2019-nCoV by World Health Organization [WHO]), and the disease caused by SARS-CoV-2 received its official name as COVID-19 later on February 11, 2020. 1 As of July 29, 2020, there were 16,341,920 confirmed COVID-19 cases worldwide, including 650,805 deaths. According to the WHO, 226,783 new cases and 4153 new deaths worldwide in the last 24 h. 2 Since the beginning of the new millennium, the rapid emergence and spread of CoVs have caused a grave loss of life and property. One of the most famous examples is the SARS-CoV, which first appeared during the winter of 2002 and caused a viral respiratory illness, namely the SARS. 3,4 The SARS epidemic had serious consequences in 29 regions and countries, with 8096 people being infected worldwide and the mortality rate reaching 9.6%. 5 Later in 2012, the MERS-CoV was first identified in a 60-year-old man who lived in the Kingdom of

show abstract

Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice

Cited by 18 publications

References 60 publications

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science

The recent challenges of highly contagious COVID‐19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy

Research progress and challenges to coronavirus vaccine development

Contact Info

Product

Resources

About